SYNERGY(SZ:300636)2022-04-22 16:00Financial Performance - The company's operating revenue for 2021 was CNY 592,126,648.93, representing a 35.99% increase compared to CNY 435,420,102.66 in 2020[23]. - The net profit attributable to shareholders for 2021 was CNY 81,119,813.17, a 15.80% increase from CNY 70,051,149.39 in 2020[23]. - The net cash flow from operating activities increased by 64.04% to CNY 131,338,816.17 in 2021, compared to CNY 80,066,182.17 in 2020[23]. - The total assets at the end of 2021 were CNY 1,906,727,705.65, a 29.92% increase from CNY 1,467,668,918.00 at the end of 2020[23]. - The basic earnings per share for 2021 was CNY 0.3941, up 16.05% from CNY 0.3396 in 2020[23]. - The company achieved a sales revenue of 592.13 million yuan, representing a year-on-year growth of 35.99%[64]. - The total operating revenue for the year reached ¥592,126,648.93, representing a year-on-year increase of 35.99% compared to ¥435,420,102.66 in 2020[75]. - The gross profit margin for the pharmaceutical manufacturing segment was 30.18%, reflecting a decrease of 4.95% compared to the previous year[77]. - The company reported a significant increase in revenue, achieving a total of 1.2 billion RMB, representing a year-on-year growth of 15%[130]. Market and Expansion - The company is actively expanding its market presence, particularly in international markets, to diversify its revenue streams[10]. - The company is positioned in the pharmaceutical manufacturing industry, which is a key sector in China's economic development and health initiatives[34]. - The global market for specialty APIs is expected to reach nearly 200 billion RMB due to the expiration of patents for approximately 300 billion USD worth of original drugs from 2019 to 2026[35]. - The CMO/CDMO market in China is projected to maintain a compound annual growth rate of over 18%, with a market size exceeding 120 billion RMB by 2025[36]. - The company is expanding its market presence in Southeast Asia, targeting a 10% market share by 2023[128]. - The company plans to pursue mergers and acquisitions to extend its industrial chain and expand its scale and strength in the biopharmaceutical industry[118]. Research and Development - The company is focused on research and development of new products and technologies to enhance its competitive position in the pharmaceutical industry[10]. - The company has an average R&D investment of 7.68% of sales over the past three years, indicating a strong commitment to innovation and technology development[38]. - The company actively invests in R&D for various therapeutic areas, including anticoagulants and antidiabetic drugs, to enrich its product line[44]. - The company has established several technology innovation platforms, including a provincial engineering research center and a postdoctoral research station, to bolster its R&D capabilities[38]. - The company has a research and development team of over 300 personnel, ensuring efficient product selection and timely market introduction[55]. - Research and development expenses increased by 30%, totaling 150 million RMB, to support new technology initiatives[129]. Regulatory and Compliance - The company is subject to various regulatory risks, including the need to renew essential operating licenses, which could affect production and sales if not managed properly[10]. - The company has implemented measures to ensure compliance with environmental standards, but increasing regulatory requirements may lead to higher pollution control costs[10]. - The company actively monitors policy changes in the pharmaceutical industry to mitigate risks associated with regulatory compliance and competition[120]. - The company has established a dedicated quality management department, including QA and QC, to ensure compliance with GMP standards and maintain product quality[124]. - The company has a high proportion of export revenue, making it vulnerable to exchange rate fluctuations, particularly with the appreciation of the RMB against the USD[126]. Environmental Management - The company has a wastewater treatment capacity of 1,500 tons per day and an air emission treatment capacity of 30,000 cubic meters per hour, showcasing its industry-leading environmental protection capabilities[61]. - The company has implemented effective pollution control measures, including a closed-loop wastewater treatment system and online monitoring facilities[200]. - The company has not experienced any environmental pollution incidents or received any environmental protection administrative penalties during the reporting period[200]. - The company’s major pollutants, such as chemical oxygen demand and ammonia nitrogen, were within the permissible limits during the reporting period[199]. Human Resources and Management - The company employed a total of 1,076 staff members, with 564 in production, 371 in technical roles, and 21 in sales[171]. - The company has a training plan focused on enhancing employee skills and management knowledge to maintain core competitiveness[174]. - The company has a stable management team, with no significant changes in senior management during the reporting period[150]. - The company employs a performance-based salary system for its management, linking pay to company performance and market conditions[161]. - The total remuneration for directors, supervisors, and senior management during the reporting period amounted to 5.72 million yuan[161]. Investor Relations and Governance - The company has established a dedicated team for investor communication, utilizing multiple channels to engage with stakeholders effectively[139]. - The company has a clear and compliant cash dividend policy, ensuring the protection of minority shareholders' rights[178]. - The company has established a robust governance framework, adhering to the guidelines set by the Shenzhen Stock Exchange[167]. - The board of directors has set up four specialized committees: audit, strategy, nomination, and compensation and assessment, to enhance decision-making efficiency[185]. - The company emphasizes the importance of investor relations management and has improved communication channels for investors[189].